Date: Sunday, November 8, 2015
Session Type: ACR Poster Session A
Session Time: 9:00AM-11:00AM
Calprotectin (S100A8/9, MRP8/14) has been demonstrated as a promising biomarker of clinical and laboratory disease activity in rheumatoid arthritis (RA). In addition, two small previous studies have shown that calprotectin might by associated with ultrasound-determined synovitis 1,2. The aim was to evaluate associations between calprotectin and conventional disease markers as well as ultrasound parameters of disease activity in a larger cohort of RA patients.
A total of 160 patients with RA (128 females, median disease duration 4.8 years) were recruited in this study. All patients underwent clinical (DAS28, CDAI, SDAI) and ultrasound examination (German US-7 score) 3. The levels of serum calprotectin and CRP were measured at the time of ultrasound assessment. Clinical and laboratory measures were correlated with ultrasound findings using Spearman´s correlation coefficient. Multiple regression analysis was used to determine the predictive value of calprotectin, CRP and DAS28 to determine GS and PD synovitis scores.
We found that calprotectin was significantly associated with DAS28 (r=0.332, p<0.001), SDAI (r=0.318, p<0.001), CDAI (r=0.294, p<0.001) and particularly with CRP levels (r=0.551, p<0.001). Moreover, calprotectin significantly correlated with GS (r=0.366, p<0.001) and PD synovitis scores (r=0.350, p<0.001). In multiple regression analysis, DAS28 and calprotectin, but not CRP, were strong predictors of GS (β=0.598, p<0.001; β=0.371, p<0.001, resp.) (adjusted R2=0.680) and PD synovitis scores (β=0.379, p<0.001; β=0.346, p<0.001, resp.) (adjusted R2=0.633).
Calprotectin is associated with clinical, laboratory and ultrasound parameters of synovial inflammation and may have an additional role in monitoring disease activity in RA.
- Hammer HB, Fagerhol MK, Wien TN, Kvien TK. The soluble biomarker calprotectin (an S100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab. Arthritis Res Ther. 2011;13(5):R178.
- Hurnakova J, Hanova P, Hulejova H, et al. Serum calprotectin (S100A8/9) correlates with clinical and ultrasound outcomes in patients with early rheumatoid arthritis. In Ann Rheum Dis. 2014; Suppl (2): 658–658.
- Backhaus TM, et al. The US7 score is sensitive to change in a large cohort of patients with rheumatoid arthritis over 12 months of therapy. Ann Rheum Dis. 2013 Jul;72(7):1163-9.
To cite this abstract in AMA style:Hurnakova J, Zavada J, Hanova P, Hulejová H, Klein M, Mann HF, Sleglova O, Olejarova M, Forejtová , Ruzickova O, Komarc M, Vencovsky J, Pavelka K, Senolt L. Serum Calprotectin Levels Correlate with Ultrasonographic Synovitis in Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/serum-calprotectin-levels-correlate-with-ultrasonographic-synovitis-in-rheumatoid-arthritis-patients/. Accessed April 9, 2020.
« Back to 2015 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-calprotectin-levels-correlate-with-ultrasonographic-synovitis-in-rheumatoid-arthritis-patients/